胡静珊

2017-06-23

  北京大学获生物系生化学士学位,于美国MD安德森癌症中心学习获德克萨斯大学生物医学研究生院博士学位,之后在哈佛医学院麻省总医院完成博士后研究。随之在美国人类基因组公司(Human Genome Sciences, Inc)任蛋白质药物研究员和VEGF2项目主管,继而加入美国 Affymetrix公司后任药理基因组学项目经理, 并成功与其它企业和学术界如斯坦福大学合作。之后加入罗氏制药公司美国 Roche Palo Alto分公司最后任职位功能生物学部门主任。随后加入美国默克(默沙东)制药公司任大中华区新药技术产品转让及合作总监。之后加入拜耳医药任副总裁及全球研发中国创新中心负责人。胡静珊自2016.3月起加入启明创投现任美国医药健康基金合伙人专注投资于美国有中国潜力的医药健康创新产业。另外她现在还任百华协会董事和美华医药协会董事。胡静珊具有许多年在三个跨国制药企业及两个美国生物技术公司从事研发、合作、转让、管理, 包括中美及中德之间合作方面资深广博的工作经验。

Dr. Jing-Shan “Jennifer” Hu joined Qiming Venture Partners in March 2016 and is now Partner of its U.S. Healthcare Fund. She brings extensive experience in partnering, licensing, business development, R&D and management from three pharmaceutical multinational companies & two U.S. biotech companies, especially cross-border partnership between China and U.S. & Europe.  Before Qiming, she was VP and Head of (External) Innovation Center China at Bayer Healthcare, responsible for partnering for Global Drug Discovery with organizations in Greater China.  Prior to that, she was Director of Licensing & External Research at Merck& Co (MSD) covering Greater China for Worldwide Licensing & External Research on novel therapeutics and technologies.  She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics & VEGF-2 Project Leader.  While working at biotech companies, she has been successful in partnering with various organizations, including biotech industry and academia such as Stanford University.  Dr. Hu obtained her post-doctoral training at Harvard Medical School and Massachusetts Hospital, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center in 1989, and BS degree in Biochemistry from Peking University in 1983.  She is also a board member at BayHelix Group and Chinese-American BioPharmaceutical Society (CABS).

上一篇:杨志
下一篇:胡旭波
Powered by 飞色网络